| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-12-04 | imetelstat | acute myelogenous leukemia |
preclinical | Geron (USA - CA) | Cancer - Oncology |
| 2014-12-04 | PM01183 (lurbinectidin) | resistant/refractory ovarian cancer | 2b | PharmaMar (Spain) | Cancer - Oncology |
| 2014-12-03 | volanesorsen (ISIS-APOCIIIRx) | familial chylomicronemia syndrome |
2a | Ionis Pharmaceuticals (USA - CA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2014-12-02 | Xyrem® (sodium oxybate) | children and adolescents aged seven to 17 who have narcolepsy with cataplexy |
3 | Jazz Pharmaceuticals (Ireland) | CNS diseases - Neurological diseases |
| 2014-12-01 | pacritinib | relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene | 2 | Cell Therapeutics, now CTI Biopharma (USA - WA) Cancer Research UK (UK) Cardiff University (UK) | Cancer - Oncology |
| 2014-12-01 | GalNAc-conjugated siRNA | Alnylam Pharmaceuticals (USA - MA) | |||
| 2014-12-01 | fingolimod | primary progressive multiple sclerosis (PPMS) |
Novartis (Switzerland) | Autoimmune diseases - Neurodegenerative diseases | |
| 2014-12-01 | tosedostat | relapsed or refractory acute myeloid leukemia (AML) |
2 | Chroma Therapeutics (UK) Cell Therapeutics (USA) | Cancer - Oncology |
| 2014-11-26 | Ebola vaccine | Ebola fever |
1 | GSK (UK) NIH (USA) | Infectious diseases |
| 2014-11-26 | caplacizumab | acquired thrombotic thrombocytopenic purpura (TTP) | 1 | Ablynx (Belgium) | Autoimmune diseases - Rare diseases |
| 2014-11-25 | VLA15 - Lyme borreliosis vaccine | Lyme borreliosis | preclinical | Valneva (France) | Infectious diseases |
| 2014-11-25 | OBT357 (MEN1112) | acute myeloid leukemia |
1 | Menarini Group (Italy) Oxford BioTherapeutics (UK) | Cancer - Oncology |
| 2014-11-24 | CART cell development programs including UCART19 | Cellectis (France) | Cancer - Oncology | ||
| 2014-11-24 | rilotumumab | advanced gastric cancer | 3 | Amgen (USA - CA) | Cancer - Oncology |
| 2014-11-24 | daratumumab | smoldering multiple myeloma | 2 | Janssen R&D, a J&J company (USA - NJ) - Genmab (Denmark) | Cancer - Oncology |
| 2014-11-24 | Yondelis® (trabectedin) | leiomyosarcoma and liposarcoma (L-type Sarcomas) |
3 | PharmaMar, Zeltia Group (Spain) Janssen Research & Development, a J&J company (USA - NJ) | Cancer - Oncology |
| 2014-11-21 | elafin | prevention of myocardial injury after coronary artery bypass surgery |
2 | Proteo (USA - NV) Proteo Biotech (Germany) | Cardiovascular diseases |
| 2014-11-20 | AUT00063 | hearing loss and tinnitus |
2a | Autifony Therapeutics (UK) | Otorhinolaryngology |
| 2014-11-20 | AZD5312 (ISIS-ARRx) | prostate cancer |
preclinical | Isis Pharmaceuticals (USA - CA) AstraZeneca (UK) | Cancer - Oncology |
| 2014-11-20 | Dendritic Cell (DC) vaccines | Medigene (Germany) | Cancer - Oncology |
